1st Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Firm
Client
Income
—
Expenses
$370,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.

LobbyistCovered position, as disclosed
JONAH C HOUTS —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Internal Revenue Service (IRS); Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL); Federal Trade Commission (FTC); White House Office; SENATE; Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO); Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Defense, Dept of (DOD)

Taxation/Internal Revenue Code TAX

HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.

LobbyistCovered position, as disclosed
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL); Congressional Budget Office (CBO); Defense, Dept of (DOD); Federal Trade Commission (FTC); Food & Drug Administration (FDA); Internal Revenue Service (IRS); White House Office; Health Resources & Services Administration (HRSA); SENATE

Bills named: H.R. 4 (112th)

Health Issues HCR

Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)

LobbyistCovered position, as disclosed
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Executive Office of the President (EOP); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); Food & Drug Administration (FDA); Government Accountability Office (GAO); Congressional Budget Office (CBO); White House Office; Defense, Dept of (DOD); U.S. Trade Representative (USTR); Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); SENATE

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: U.S. Trade Representative (USTR); Defense, Dept of (DOD); Internal Revenue Service (IRS); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office; Food & Drug Administration (FDA); SENATE; Federal Trade Commission (FTC); Congressional Budget Office (CBO); Government Accountability Office (GAO); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL)

Bills named: H.R. 905 (112th), H.R. 2190 (112th), H.R. 891 (112th), H.R. 4215 (112th), H.R. 2248 (112th)

Labor Issues/Antitrust/Workplace LBR

Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Federal Trade Commission (FTC); Internal Revenue Service (IRS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); White House Office; Congressional Budget Office (CBO); Defense, Dept of (DOD); SENATE; Executive Office of the President (EOP); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS)

Bills named: H.R. 1409 (112th), H.R. 1839 (112th), H.R. 1946 (112th)

Pharmacy PHA

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); SENATE; Executive Office of the President (EOP); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Defense, Dept of (DOD); White House Office; Labor, Dept of (DOL); Federal Trade Commission (FTC)

Bills named: H.R. 1971 (112th), H.R. 979 (112th), S. 27 (112th)

Defense DEF

Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012.

LobbyistCovered position, as disclosed
NANCY GILBRIDE —
MARY M ROSADO —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); Internal Revenue Service (IRS); Government Accountability Office (GAO); Labor, Dept of (DOL); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); White House Office; Health Resources & Services Administration (HRSA); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Defense, Dept of (DOD)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.